hrp0084p3-763 | Diabetes | ESPE2015

Maturity Onset Diabetes of the Young: Just Think about It

Messaaoui Anissa , Tenoutasse Sylvie , Dorchy Harry

Background: Maturity Onset Diabetes of the Young (MODY) is a monogenic form of diabetes with onset before 25 years. It is a heterogeneous disorder due to heterozygous monogenic mutations with an autosomal dominant transmission. It represents 2 to 5 percent of diabetes but is often underdiagnosed. We report three cases of MODY highlighting the features of different subtypes, two without associated abnormalities and one with renal disorder.Cases presentati...

hrp0094fc4.4 | Diabetes | ESPE2021

Effect of newer CFTR modulator therapy on glycaemic control in adolescents with CFRD

Park Julie , Walsh Anna , Kerr Sue , Woodland Clare , Southward Suzanne , Deakin Mark , Thursfield Rebecca , Senniappan Senthil ,

Background: Cystic fibrosis related diabetes (CFRD) affects 40-50% of adults with Cystic Fibrosis (CF) and significantly decreases pulmonary function and affects life expectancy. Previous data highlighted that CFRD may be preventable or curable with the use of CFTR modulators, namely Ivakaftor. Kaftrio (Ivakaftor, tezacaftor and elexacaftor) has recently been licensed for use in CF. To our knowledge, its effect on glucose regulation in children and young peopl...

hrp0086p1-p735 | Pituitary and Neuroendocrinology P1 | ESPE2016

Prolactinomas in Children and Young Adults: 10 Year Experience in a Tertiary Regional Paediatric - Young Adult - NeuroEndocrine Surgical Centre

Kalitsi J , Kapoor RR , Kalogirou N , Thomas NP , Aylwin SJB , Buchanan CR

Background: Prolactinomas are rare in the prepubertal and adolescent age group. Therapeutic approaches are guided by experience from treating adults. Few series have been reported.Objective: Retrospective analysis of presenting features, treatment and outcomes in young patients presenting to a Tertiary Endocrine Service (total referral population ~3.5 million) managed jointly between Paediatric and Adult Endocrine and Neurosurgical services.<p class=...

hrp0086p2-p671 | Growth P2 | ESPE2016

Assessing Disease and Treatment Burden for Young Children with Growth Hormone Deficiency (GHD)

Brod Meryl , Wilkinson Lars , Alolga Suzanne Lessard , Hojbjerre Lise , Beck Jane , Rasmussen Michael Hojby

Background: Children with GHD, in addition to short stature, may experience physiological symptoms as well as social and emotional problems. Assessing these impacts is critical for understanding the extent of GHD burden and assessing treatment benefit. Since many children initiating treatment are too young to self-report information, we must rely on adult reporters. However, according to FDA guidelines and established measure development principles, adult reporter information ...

hrp0082p3-d1-929 | Puberty and Neuroendocrinology | ESPE2014

Long-Term Consequences of Indirect Topical Exposure to Testosterone Gel in Young Children

Gies Inge , Vanbesien Jesse , De Brucker Yannick , Ernst Caroline , Anckaert Ellen , De Schepper Jean

Background: Virilization of young children after topical androgen use by their fathers through skin contact is well-known. The long-term consequences of such exposure at very young age are not well known.Objective and hypotheses: The aim is to report the occurrence of spermarche in a young boy and central precocious puberty in a young girl as late consequences of interpersonal transfer of testosterone gel.Method: Testosterone conta...

hrp0094p2-336 | Multisystem endocrine disorders | ESPE2021

Endocrine and metabolic complications according to genotype in Prader-Willi syndrome

Young Yoon Ju , Dong Yoo Suk , Abdumonnanovich Mamatkulov Elbek , Nailevich Gilyazetdinov Kamil , Cheon Chong Kun ,

Objective: Prader-Willi syndrome (PWS) is a complex genetic disease associated with hypothalamic-pituitary dysfunction, severe obesity and metabolic dysfunctions. The aim of this study was to describe endocrine and metabolic profiles in PWS children and young adults.We also investigated the differences in clinical outcomes according to genotype.Methods: Data of 64 children and adults with genetically verified PWS aged mo...

hrp0092p3-122 | Fat, Metabolism and Obesity | ESPE2019

The Characteristic of Thyroid Status in Overweight and Obese Young People with Insulin Resistance

Tolstikova Olena , Aharkov Serhii

Introduction: Due to the widespread occurrence of both obesity and hypothyroidism, physicians need to be especially attentive to the possible thyroid dysfunction in obese patients. The relationship between thyroid hormones and obesity in combination with insulin resistance in young people is not fully understood.Materials and Methods: In order to study of thyroid status in young people with overweight and obesity in comb...

hrp0095t13 | Section | ESPE2022

Impact on predicted adult height and basal gonadotropin levels through triptorelin 6-month formulation in patients with central precocious puberty

Joo Yoo Eun , Yang Aram , Jun Choi Yong

Background: Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, is available as 1-, 3-, and 6-month formulation for treatment of central precocious puberty (CPP). The triptorelin 22.5mg as 6-month formulation, which has recently been approved for use in CPP and offers greater convenience to children by reducing the injection frequency, but related research is very limited. The aim of this study was to study on the impact of 6 month formulation on pre...

hrp0095t17 | Section | ESPE2022

Impact on predicted adult height and basal gonadotropin levels through triptorelin 6-month formulation in patients with central precocious puberty

Joo Yoo Eun , Yang Aram , 아람 양

Background: Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, is available as 1-, 3-, and 6-month formulation for treatment of central precocious puberty (CPP). The triptorelin 22.5mg as 6-month formulation, which has recently been approved for use in CPP and offers greater convenience to children by reducing the injection frequency, but related research is very limited. The aim of this study was to study on the impact of 6 month formulation on pre...

hrp0082p1-d3-81 | Diabetes (2) | ESPE2014

mHealth app for Young People with Diabetes Type 1 Transferring from Pediatric to Adult Care

Teilmann Grete , Boisen Kirsten , Hommel Eva , Olsen Birthe , Pedersen-Bjergaard Ulrik , Castensoe-Seidenfaden Pernille

Background: Managing diabetes requires self-care, knowledge and support – especially when moving from pediatric to adult care. Finding ways to empower young people in transition and transfer is therefore important.Objective: To develop, test and evaluate a mHealth app for young people with diabetes type 1 transferring from pediatric to adult care.Method: Development: We developed an app-prototype based on rapid prototyping and...